Bibliografía:
1. Persaud S.J., Jones P.M., A wake-up call for type 2 diabetes?,
N. Engl. J. Med., 2016,
375: 1090–1092.
2. Alegre-Diaz J., Herrington W., Lopez-Cervantes M. y cols., Diabetes and cause-specific
mortality in Mexico City. N. Engl. J. Med., 2016, 375: 1961–1971.
3. Nanditha A., Ma R.C.W., Ramachandran A. y cols., Diabetes in Asia and the Pacific:
implications for the global epidemic,
Diabetes Care, 2016, 39: 472–485.
4. Riddle MC: Basal glucose can be controlled, but the prandial problem persists – it’s
the next target!,
Diabetes Care, 2017, 40: 291–300.
5. US Food and Drug Administration: Clinical perspectives on FDA guidance for industry:
diabetes mellitus: evaluating CV risk in new anti-diabetic therapies to treat T2DM. http://
www.fda.gov/downloads/Drugs/NewsEvents/UCM209 087.pdf. Accessed 29 Jan.2016
6. Regier EE, Venkat MV, Close KL: More than 7 years of hindsight: revisiting the FDA
2008 Guidance on Cardiovascular Outcomes trials for type 2 diabetes medications,
Clin.
Diabetes, 2016, 34: 173–180.
7. American Diabetes Association: Report of the expert committee on the diagnosis and
classification of diabetes mellitus,
Diabetes Care, 1997, 20: 1183–1197.
8. WHO: Definition, diagnosis and classification of diabetes mellitus and its complications.
Report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus.
WHO, Geneva, 1999.
9. Yudkin J.S., “Prediabetes”: Are there problems with this label? Yes, the label creates
further problems!,
Diabetes Care, 2016, 39: 1468–1471.
10. Cefalu W.T., “Prediabetes”: Are there problems with this label? No, we need heightened
awareness of this condition!,
Diabetes Care, 2016, 39: 1472–1477.
11. Schwarz S.S., Epstein S., Corkey B.E. y cols., The time is right for a new classification
system for diabetes: rationale and implications of the beta-cell-centric classification
schema,
Diabetes Care, 2016, 39: 179–186
12. Skyler J.S., Bakris G.L., Bonifacio E. y cols., Differentiation of diabetes by pathophysiology,
natural history, and prognosis,
Diabetes, 2017, 66: 241–255.
13. American Diabetes Association: Standards of medical care in diabetes – 2017. 2.
Classification and diagnosis of diabetes,
Diabetes Care, 2017, 40 (supl. 1): S11–S24.
14. White M.G., Shaw J.A.M., Taylor R., Type 2 diabetes: the pathologic basis of reversible
dysfunction,
Diabetes Care, 2016, 39: 2080–2088.
15. Wanner C., Inzucchi S.E., Lachin J.M. y cols., Empagliflozin and progression of kidney
disease in type 2 diabetes,
N. Engl. J. Med., 2016, 375: 323–334.
16. Zinman B., Wanner C., Lachin J.M. y cols., Empagliflozin, cardiovascular outcomes, and
mortality in type 2 diabetes,
N. Engl. J. Med., 2015, 373: 2117–2128.
17. Rosenstock J., Chuck L., Gonzalez-Ortiz M. y cols., Initial combination therapy with
canagliflozin plus metformin versus each component as monotherapy for drug-naive
type 2 diabetes,
Diabetes Care, 2016, 39: 353–362.
18. Davies M.J., Bain S.C., Atkin S.L. y cols., Efficacy and safety of liraglutide versus placebo as
add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal
impairment (LIRA-RENAL): a randomized clinical trial,
Diabetes Care, 2016, 39: 222–230.
19. Cornel J.H., Bakris G.L., Stevens S.R. y cols., Effect of sitagliptin on kidney function and
respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS,
Diabetes
Care, 2016, 39: 2304–2310.
20. Kalantar-Zadehy K., Kovesdy C.P.: Should restrictions be relaxed for metformin use in
chronic kidney disease? No, we should never again compromise safety!,
Diabetes Care,
2016, 39: 1281–1286.
21. Bakris G.L., Molitch M.E., Should restrictions be relaxed for metformin use in chronic
kidney disease? Yes, they should be relaxed! What the fuss?,
Diabetes Care, 2016, 39:
1287–1291.
22. Ragot S., Saulnier P.-J., Velho G. y cols., Dynamic changes in renal function are associated
with major cardiovascular events in patients with type 2 diabetes,
Diabetes Care,
2016, 39: 1259–1266.
23. Ku E., McCulloch C.E., Mauer M. y cols., Association between blood pressure and adverse
renal events in type 1 diabetes,
Diabetes Care, 2016, 39: 2218–2224.
24. Li L., Jick S., Breitenstein S., Michel A.: Prevalence of diabetes and diabetic nephropathy
in a large US. Commertially insured pediatric population 2002–2013,
Diabetes Care,
2016, 39: 278–284.
25. Russo G.T., De Cosma S., Viazzi F. y cols., Plasma triglycerides and HDL-C levels predict
the development of diabetic kidney disease in subjects with type 2 diabetes: the AMD
Annals Initiative,
Diabetes Care, 2016, 39: 2278–2287.
26. Wong M.G., Perkovic V., Chalmers J. y cols., Long-term benefits of intensive glucose control
for preventing end-stage kidney disease: ADVANCE-ON,
Diabetes Care, 2016, 39: 694–700.
27. Novak M., Mucsi I., Rhee C.M. y cols., Increased risk of incident chronic kidney disease,
cardiovascular disease, and mortality in patients with diabetes with comorbid depression,
Diabetes Care, 2016, 39: 1940–1949.
28. Tagawa A., Yasuda M., Kume S. y cols., Impaired podocyte autophagy exacerbates
proteinuria in diabetic nephropathy,
Diabetes, 2016, 65: 755–767.
29. Niewczas M., Mathew A.V., Croall S. y cols., Circulating modified metabolites and risk
of ESRD in patients with type 1 diabetes and chronic kidney disease,
Diabetes Care,
2017, 40: 383–390.
30. Skupień J., Warram J.H., Smiles A.M. y cols., Patterns of estimated glomerular filtration
rate decline leading to end-stage renal disease in type 1 diabetes,
Diabetes Care, 2016,
39: 2262–2269.
31. Church T.J., Haines S.T.: Treatment approach to patients with severe insulin resistance,
Clin. Diabetes, 2016, 34: 97–104.
32. Kernan W.N., Viscoli C.M., Furie K.L y cols., Pioglitazone after ischemic stroke or transient
ischemic attack,
N. Engl. J. Med., 2016, 374: 1321–1331.
33. Inzucchi S.E., Viscoli C., Young L.H. y cols., Pioglitazone prevents diabetes in patients
with insulin resistance and cerebrovascular disease,
Diabetes Care, 2016, 39: 1684–1692.
34. Semenkovich C.F., Insulin resistance and a long, strange trip,
N. Engl. J. Med., 2016,
374: 1378–1379.
35. Malone J.I., Diabetic central neuropathy: CNS damage related to hyperglycemia,
Diabetes,
2016, 65: 355–357.
36. Mazaika P.K., Weinzimer S.A., Mauras N. y cols., Variations in brain volume and growth
in young children with type 1 diabetes,
Diabetes, 2016, 65: 476–485.
37. Liu R., Wang H., Xu B. y cols., Cerebrovascular safety of sulfonylureas: the role of KATP
channels in neuroprotection and the risk of stroke in patients with type 2 diabetes,
Diabetes, 2016, 65: 2795–2809.
38. Pop-Busui R., Boulton A.J.M., Feldman E.L. y cols., Diabetic neuropathy: a position
statement by the American Diabetes Association,
Diabetes Care, 2017, 40: 136–154.
39. American Diabetes Association: Standards of medical care in diabetes – 2017.
Microvascular complications and food care,
Diabetes Care, 2017, 40 (supl. 1): S88–S98.
40. Vinik A.I.: Diabetic sensory and motor neuropathy,
N. Engl. J. Med., 2016, 374: 1455–1464.
41. Almurdhi M.M., Reeves N.D., Bowling F.L. y cols., Reduced lower-limb muscle strength
and volume in patients with type 2 diabetes in relation to neuropathy, intramuscular
fat, and vitamin D levels,
Diabetes Care, 2016, 39: 441–447.
42. Callaghan B.C., Xia R., Banerjee M. y cols., Metabolic syndrome components with symptomatic
polyneuropathy independent of glycemic status,
Diabetes Care, 2016, 39: 801–807.
43. Mundinger T.O., Mei Q., Foulis A.K. y cols., Human type 1 diabetes is characterized by
an early, marked, sustained, and islet-selective loss of sympathetic nerves,
Diabetes,
2016, 65: 2322–2330.
44. Von Scholten B.J., Hansen C.S., Hasbak P. y cols., Cardiac autonomic function is associated
with the coronary microcirculatory function in patients with type 2 diabetes,
Diabetes,
2016, 65: 3129–3138.
45. Hataling J.M., Sarma A.V., Patel D.P. y cols., Cardiovascular autonomic neuropathy,
sexual dysfunction, and urinary incontinence in women with type 1 diabetes,
Diabetes
Care, 2016, 39: 1587–1593.
46. Rohling M., Strom M., Bonhof G. y cols., Differential patterns of impaired cardiorespiratory
fitness and cardiac autonomic dysfunction in recently diagnosed type 1 and type 2 diabetes,
Diabetes Care, 2017, 40: 246–252.
47. Polskie Towarzystwo Diabetologiczne: Zalecenia kliniczne dotycz±ce postępowania u chorych na cukrzycę 2017. Okre¶lenie celów leczenia cukrzycy,
Diabetol. Prakt., 2017, 3 (supl. A): A9–A11.
48. Brahimaj A., Ligthart S., Ikram M.A. y cols., Serum levels of apolipoproteins and incident
type 2 diabetes: a prospective study,
Diabetes Care, 2017, 40: 346–351.
49. Hero C., Rawshani A., Svensson A.-M. y cols., Association between use of lipid-lowering
therapy and cardiovascular diseases and death in individuals with type 1 diabetes,
Diabetes Care, 2016, 39: 996–1003.
50. Azad N., Bahn G.D., Emanuele N.V. y cols., Association of blood glucose control and
lipids with diabetic retinopathy in the Veterans Affaires Diabetes Trial (VADT),
Diabetes
Care, 2016, 39: 816–822.
51. Lu L., Koulman A., Petry C.J. y cols., An unbiased lipidomics approach identifies early
second trimester lipids predictive of maternal glycemic traits and gestational diabetes
mellitus,
Diabetes Care, 2016, 39: 2232–2239.
52. Polskie Towarzystwo Diabetologiczne: Zalecenia kliniczne dotycz±ce postępowania u chorych na cukrzycę 2017. Cukrzyca a ci±ża,
Diabetol. Prakt., 2017, 3 (supl. A): A53–A56.
53. Waters T.P., Dyer A.R., Scholtens D.M. y cols., Maternal and neonatal morbidity for
women who would be added to the diagnosis of GDM using IADPSG criteria: a secondary
analysis of the Hyperglycemia and Adverse Pregnancy Outcome study,
Diabetes Care,
2016, 39: 2204–2210.
54. Moses R.G., Wong V.C.K., Lambert K. y cols., Seasonal changes in the prevalence of
gestational diabetes mellitus,
Diabetes Care, 2016, 39: 1218–1221.
55. Sovio U., Murphy H.R., Smith G.C.S.: Accelerated fetal growth prior to diagnosis of
gestational diabetes mellitus: a prospective cohort study of nulliparous women,
Diabetes
Care, 2016, 39: 982–987.
56. Moses R.G., Cefalu W.T., Considerations in the management of gestational diabetes
mellitus: “You are what your mother ate!”,
Diabetes Care, 2016, 39: 13–15.
57. Schoenaker D.A.J.M., Mishra G.D., Callaway L.K., Soedamach-Muthu S.S.: The role of
energy, nutrients, foods and dietary patterns in the development of gestational diabetes
mellitus: a systematic review of observational studies,
Diabetes Care, 2016, 39: 16–23.
58. Markovic T.P., Muirhead R., Overs S. y cols., Randomized controlled trial investigating
the effects of a low-glycemic index diet on pregnancy outcomes in women at high risk
of gestational diabetes mellitus: the GI baby study,
Diabetes Care, 2016, 39: 31–38.
59. Koivusalo S.B., Rono K., Klemetti M.M. y cols., Gestational diabetes mellitus can be
prevented by lifestyle intervention: the Finnish Gestational Diabetes Prevention Study
(RADIEL). A randomized controlled trial,
Diabetes Care, 2016, 39: 24–30.
60. Ferrara A., Hedderson M.M., Brown C.L. y cols., The comparative effectiveness of diabetes
prevention strategies to reduce postpartum weight retention in women with gestational
diabetes mellitus: the gestational diabetes effects on moms (GEM) cluster randomized
controlled trial,
Diabetes Care, 2016, 39: 65–74.
61. Sweeting A.N., Ross G.P., Hyett J. y cols., Gestational diabetes mellitus in early pregnancy:
evidence for poor pregnancy outcomes despite treatment,
Diabetes Care, 2016, 39: 75–81.
62. Klingensmith G.J., Pyle L., Nadeau K.J. y cols., Pregnancy outcomes in youth with type 2 diabetes: the TODAY Study experience,
Diabetes Care, 2016, 39: 122–129.
63. Sellers E.A.C., Dean H.J., Shafer L.A. y cols., Exposure to gestational diabetes mellitus:
impact on the development of early-onset type 2 diabetes in Canadian first nations and
non-first nations offspring,
Diabetes Care, 2016, 39: 2240–2246.
64. Appiah D., Schreiner P.J., Gunderson E.P. y cols., Association of gestational diabetes
mellitus with left ventricular structure and function: the CARDIA study,
Diabetes Care,
2016, 39: 400–407.
65. Syngelaki A., Nicolaides K.H., Balani J. y cols., Metformin versus placebo in obese pregnant
women without diabetes mellitus,
N. Engl. J. Med., 2016, 374: 434–443.
66. Nachum Z., Zafran N., Salim R. y cols., Glyburide versus metformin and their combination
for the treatment of gestational diabetes mellitus: a randomized controlled study,
Diabetes Care, 2017, 40: 332–337.
67. FDA 2016, http://www.accesdata.fda.gov. /cdrh_docs/pdf16/P160017a.pdf
68. FDA 2017, http://www.clinicaltrials.gov/
69. Stewart Z.A., Wilinska M.E., Hartnell S. y cols., Closed-loop insulin delivery during pregnancy
in women with type 1 diabetes,
N. Engl. J. Med., 2016, 375: 644–654.
70. Kovatchev B., Tamborlane W.V., Cefalu W.T., Cobelli C.: The artificial pancreas in 2016: a digital treatment ecosystem for diabetes,
Diabetes Care, 2016, 39: 1123–1126.
71. Anderson S.M., Raghinaru D., Pinsker J.E. y cols., Multinational home use of closed-loop
control is safe and effective,
Diabetes Care, 2016, 39: 1143–1150.
72. Renard E., Forret A., Kropff J. y cols., Day-and-night closed-loop glucose control in patients
with type 1 diabetes under free-living conditions: results of a single-arm 1-month
experience compared with previously reported feasibility study of evening and hirht
at home,
Diabetes Care, 2016, 39: 1151–1160.
73. Del Favero S., Boscari F., Messori M. y cols., Randomized summer camp crossover trial
in 5- to 9-year-old children: outpatient wearable artificial pancreas is feasible and safe,
Diabetes Care, 2016, 39: 1180–1185.
74. Tauschmann M., Allen J.M., Wilinska M.E. y cols., Home use of day-and-night hybrid
closed-loop insulin delivery in suboptimally controlled adolescents with type 1 diabetes: a 3-week, free-living, randomized crossover trial,
Diabetes Care, 2016, 39: 2019–2025.
75. Maahs D.M., Buckingham B.A., Castle J.R. y cols., Outcome measures for artificial pancreas
clinical trials: a consensus report,
Diabetes Care, 2016, 39: 1175–1179.
76. Ruan Y., Thabit H., Leelaranthna L. y cols., Variability of insulin requirements over 12
weeks of closed-loop insulin delivery in adults with type 1 diabetes,
Diabetes Care,
2016, 39: 830–832.
77. Peters A.L., Ahmann A.J., Battelino T. y cols., Diabetes technology – continuous subcutaneous
insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine
Society Clinical Practice Guideline,
J. Clin. Endocr. Metab., 2016, Sept 2, doi: 10.1210/
jc.2016–2534
78. Spaic T., Driscoli M., Raghinaru D. y cols., Predictive hypeglycemia and hypoglycemia
minimalization: in-home evaluation of safety, feasibility, and efficacy in overnight glucose
control in type 1 diabetes,
Diabetes Care, 2017, 40: 359–366.
79. Kropff J., Chaudhary P., Neupane S. y cols., Accuracy and longevity of an implantable
continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter,
pivotal trial,
Diabetes Care, 2017, 40: 63–68.
80. Tanenbaum M.L., Hanes S.J., Miller K.M. y cols., Diabetes device use in adults with
type 1 diabetes: barriers to uptake and potential intervention targets,
Diabetes Care,
2017, 40: 181–187.
Español
Polski
English
українська
